Cambridge Healthtech Institute Organizes a Summit on Immunogenicity Prediction & Mitigation

Aug. 5, 2011 - PRLog -- The Immunogenicity Prediction & Mitigation summit (part of CHI's Third Annual Immunogenicity Summit) to take place on November 17-18, 2011 at the DoubleTree Hotel in Bethesda, MD, examines advances in predictive immunogenicity and means of controlling it with a wide range of approaches. The roles of T regulatory cells and potentially tolerogenic peptides, especially Fc fusion proteins, in tolerance induction will be explored. Moreover there will be a focus on identification, modification and removal of epitopes to minimize immunogenicity risk. Sub-visible particles and aggregates are becoming extremely hot, especially from a regulatory perspective and an entire half-day will be devoted to recommended strategies for their assessment and characterization. Daniela Verthelyi, M.D., Ph.D., Chief, Laboratory of Immunology, Therapeutic Proteins, CDER, FDA, will deliver the keynote presentation titled “Innate Immune Response Modulating Impurities.” This talk will review recent data, present a few cases, and discuss the role of trace levels of impurities in therapeutic proteins that stimulate the innate immune response in facilitating an immunogenic response to therapeutic proteins.

Delegates are invited to arrive early for part one of the Immunogenicity Summit: Immunogenicity Assessment and Clinical Relevance (Nov. 16-17).

For more information and to register, please visit http://www.healthtech.com/imn. Those that register by August 26 will save up to $350.

To inquire about sponsoring and/or exhibiting, contact Katelin Fitzgerald, 781-972-5458, kfitzgerald@healthtech.com.  

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding, tfielding@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com